Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis
Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.


GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Global Medical Cannabis Market Drivers:
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(58)
•••
Comment by SamV21on Jan 17, 2022 8:45pm
185 Views
Post# 34326720

RE:Global Medical Cannabis Market Drivers:

RE:Global Medical Cannabis Market Drivers:All wonderful news, I don't see the words Tetra Bio Pharma anywhere .They have no drugs and make no money, they don't have the money to finish the drugs they are working on , too bad they won't be part of this generic message. Lets talk reality, they have reduvo maybe in 6 months, which might pull in 6 million a year for them , Qixleef is at least 500,000,000 and 4 to 5 years away from being marketed so how does this warm fuzzy message you posted have anything to do with tetra  ? Funny thing I went to IMARC Group website and typed in Tetra Bio Pharma , nothing came up , Teva came up saying they dominate the generic drug market, who is working with Tilray on bringing Syqe to market which had Health Canadas approval in April 2021.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities